Virpax Pharmaceuticals, Inc. (VRPX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VRPX Stock Price Chart Interactive Chart >
VRPX Price/Volume Stats
| Current price | $1.43 | 52-week high | $36.00 |
| Prev. close | $1.37 | 52-week low | $1.19 |
| Day low | $1.37 | Volume | 68,000 |
| Day high | $1.46 | Avg. volume | 188,421 |
| 50-day MA | $1.83 | Dividend yield | N/A |
| 200-day MA | $4.35 | Market Cap | 16.75M |
Virpax Pharmaceuticals, Inc. (VRPX) Company Bio
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company. The Company focuses on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology.
Latest VRPX News From Around the Web
Below are the latest news stories about Virpax Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRPX as an investment opportunity.
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19BERWYN, Pa., February 15, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, has been featured in several news outlets discussing potential solutions for two pressing issues: the opioid epidemic and the COVID pandemic. |
Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic PainBERWYN, Pa., February 10, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, reported promising results from preclinical dose range finding studies for Envelta (NES100), Virpax’s endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer. These findings complement previous p |
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the KneeLAVAL, Quebec, January 21, 2022--Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. ("Virpax") (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. |
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™BERWYN, Pa., January 18, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders, and anti-viral indications, reported positive results of four preclinical dermal safety studies for Epoladerm™ (diclofenac epolamine). Epoladerm is an investigational product candidate for the management of pain associated with osteoarthritis of the knee. From these recently concluded animal studies, r |
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual ConferenceBERWYN, Pa., January 04, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, J |
VRPX Price Returns
| 1-mo | -18.29% |
| 3-mo | -30.75% |
| 6-mo | -65.63% |
| 1-year | -66.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -58.31% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...